Clinical Trials

The Early Phase Trials team have decided to suspend recruitment of patients as a result of the evolving situation with COVID-19. We feel that this is appropriate and takes into consideration multiple factors such as the risk to patients associated with increased travelling, additional hospital visits to Addenbrooke's and concerns about the uncertainty of possible side effects associated with experimental therapy (such as myelo- and immuno-suppression or pneumonitis).

At this time, we are only able to offer an outpatient consultation, preferably “remotely” so that we avoid additional hospital visits, during which time we can start to discuss what taking part in trials might involve.

These decisions will remain under regular review and will be updated as new information becomes available. (Last updated 24/04/2020)

Trial Short Name Molecular Target(s)   Patient Population Lead Investigator(s)
in Cambridge
AZD1390 ATM with RT Glioblastoma  S Jeffries / G Doherty
Basket of Baskets PD-L1 Solid tumours with high mutational load/MSI  R Baird
CALIBRATION ctDNA evaluation Advanced oesophageal malignancies S Pacey
 CamBMT1 phase II  EGFR/HER2 Operable brain metastasis (breast/lung)   R Baird
CT7001 CDK7 Metastatic or locally advanced triple-negative breast cancer R Baird
GO40782  NTRK1/2/3 Proven NTRK1/2/3 gene rearrangements   S Pacey
LEAP-005 PD-1 & RTK Advanced TNBC, ovarian cancer, gastric cancer, GBM or BTC B Basu 
OUTREACH CEBPα Hepatocellular carcinoma   B Basu
PATRIOT ATR Any tumour type – palliative radiotherapy combined with ATR inhibitor  R Baird 
POSEIDON phase II PI3K HR+ metastatic breast cancer R Baird
MOv18 igE α-folate receptor  Gyane aFR+ B Basu
BOSTON Mps1 Advanced nonhaematological malignancies B Basu 
MP0274 HER2 HER2+ solid tumours R Baird
Atrium ATR Solid tumours D Jodrell
AZD9833 ER ER+ HER2- advanced breast cancer R Baird
PARADIGM-2 PARP Glioblastoma  S Jefferies/ R Baird